Why the CAP No Longer Supports 'Excited Delirium' as a Cause of Death - January 2024 Advocacy Recap

Update: CAPcasts now on CAP.org

CAPcasts are now available on cap.org and the MyCAP app: https://www.cap.org/member-resources/podcasts Download MyCAP for iOS and Android: https://apps.apple.com/us/app/mycap-cap-member-app/id1575620028 https://play.google.com/store/apps/details?id=org.cap.member.app You can also subscribe on the following podcast platforms: Apple Podcasts: https://podcasts.apple.com/us/podcast/capcasts/id1279391140 Amazon Music: https://music.amazon.com/podcasts/161134c5-94fd-460e-87ef-18cc27f8003c/capcasts

Commemorating World Cancer Day

World Cancer Day is recognized around the world on February 4th to raise awareness of and encourage the prevention, detection, and treatment of cancer. To commemorate World Cancer Day, Gladell Paner, MD, FCAP, chatted with M.E. de Baca, MD, FCAP, and Gail Vance, MD, FCAP, about how the CAP is addressing barriers to health equity through the Cancer Protocols, Council on Informatics and Pathology Innovation, and the CAP Foundation Global Pathology Committee. Learn more about the CAP Foundation: https://foundation.cap.org/ CAP Foundation 2023 Webinar Series: https://brnw.ch/CAPF2023Webinars

Why the CAP No Longer Supports 'Excited Delirium' as a Cause of Death - January 2024 Advocacy Recap

This month we'll look at a prior authorization rule that could pave the way for legislation to reduce burdens on clinicians, a grant awarded to the CAP to improve healthcare communication, action on Medicare cuts, and more. We'll also sit down with Anna Tart, MD, FCAP, to talk about why the CAP no longer supports 'excited delirium' as an official cause of death.

What Pathologists Need to Know About HER2 Testing Guidelines

Jason Scapa, MD, FCAP, Chair of the Digital Content Committee talks with Andrew Bellizzi, MD, FCAP, Past Chair of the Immunohistochemistry (IHC) Committee and current IHC Committee Member Gregory Bean, MD, PhD, FCAP, about the latest update to HER2 Breast Cancer Testing Guidelines. Issued in June 2023, the CAP and the American Society of Clinical Oncology (ASCO) have reaffirmed the 2018 "HER2 Breast Testing Guideline Focused Update" in response to the results of the 2022 DESTINY-Breast04 trial. CAP HER2 Guideline: https://www.cap.org/protocols-and-guidelines/cap-guidelines/current-cap-guidelines/recommendations-for-human-epidermal-growth-factor-2-testing-in-breast-cancer

December 2023 Advocacy Recap

This month we’ll take a look at efforts to mitigate recent Medicare cuts, digital and cybersecurity news in the health care sector, and more.